Serous cystadenocarcinoma ovary – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Serous cystadenocarcinoma ovary – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Paclitaxel, Carboplatin and Letrozole Treatment Compared to Letrozole Alone in Patients with Stage II-IV Low-Grade Serous Ovarian or Peritoneal Cancer https://clinicaltrials.eu/trial/study-comparing-letrozole-alone-to-paclitaxel-carboplatin-and-letrozole-for-women-with-stage-ii-iv-low-grade-serous-ovarian-or-peritoneal-cancer/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-comparing-letrozole-alone-to-paclitaxel-carboplatin-and-letrozole-for-women-with-stage-ii-iv-low-grade-serous-ovarian-or-peritoneal-cancer/ This study focuses on low-grade serous carcinoma of the ovary or peritoneum. The research compares two treatment approaches: one group receives a combination of paclitaxel and carboplatin followed by letrozole maintenance therapy, while the other group receives letrozole treatment alone. Letrozole is a medication that helps block the production of estrogen, which can fuel the growth of certain cancers.

The medications used in this study include chemotherapy drugs given through an intravenous infusion (paclitaxel and carboplatin) and hormone therapy tablets (letrozole). Other hormone therapy medications that may be used include anastrozole and exemestane. The purpose is to determine if using letrozole alone works as well as combining chemotherapy with letrozole maintenance therapy for treating this type of cancer.

During the study, patients will be randomly assigned to one of two treatment groups. One group will receive chemotherapy infusions followed by daily letrozole tablets, while the other group will take only letrozole tablets. The treatment and follow-up period will continue for several years to monitor how well the cancer responds to these treatments.

]]>